Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.259 | N/A |
Market Cap | $35.37M | N/A |
Shares Outstanding | 136.55M | 0.87% |
Employees | 0 | N/A |
Shareholder Equity | 24.62M | -1.26% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 2.92 | N/A |
P/B Ratio | 1.44 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0012 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $12.13M | N/A |
Earnings | -$29.00K | N/A |
Gross Margin | 0.453 | N/A |
Operating Margin | -0.1657 | N/A |
Net income margin | -0.0024 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $26.19M | N/A |
Total Debt | $4.88M | N/A |
Cash on Hand | $8.53M | N/A |
Debt to Equity | 0.3290 | 36.10% |
Cash to Debt | $1.75 | -24.59% |
Current Ratio | $5.13 | -39.36% |